While the indigenous malaria vaccine, AdFalciVax, is under evaluation, a dengue vaccine is currently in Phase 3 trials with ...

Dengue vaccine Qdenga is likely to be arrive in India early next year. Is this a new vaccine? Can it stop outbreaks? Who can ...

Qdenga, cleared this week for ages 4 to 60, is one of only a few dengue vaccines in the world. It is to be injected in two doses three months apart.

India approved its first dengue vaccine, Takeda's QDENGA, for ages 4–60. The two-dose vaccine protects against all four strains, cuts severe disease and hospitalisation, and complements mosquito ...

India may see its first dengue vaccine, Qdenga, by 2027. Approved for ages 4–60, it aims to reduce disease severity but may ...

A study suggests the hexavalent vaccine could enhance India's immunisation efficiency by reducing injections and easing ...

India plans to launch its indigenous malaria vaccine before 2030, a target set by the Centre to eradicate the disease.

The virus itself makes no distinction between sexes. It spreads through skin-to-skin contact, most commonly during sexual ...

Takeda's QDENGA has been approved for people aged 4–60, offering a new prevention tool as dengue cases and the wider disease burden remain a public health challenge.

India has approved its first dengue vaccine, QDENGA, in a step against a disease that has become an increasingly large public health challenge in the country.

India approves its first dengue vaccine, Takeda's Qdenga, effective against all four dengue strains and usable without pre-vaccination screening, aiming to combat rising dengue cases nationwide.

ICAR's new vaccine for African Swine Fever aims to reduce pig mortality and strengthen India's biosecurity and farmers' ...